NewAmsterdam Pharma Company N.V.
NAMSNASDAQ
Healthcare
Biotechnology
$33.90
+0.91(2.8%)
52W $14.90 – $41.45
NewAmsterdam Pharma Company N.V.
$3.9BMkt Cap
$23MRev TTM
-$205MNI TTM
-16.8xP/E TTM
Latest Earnings
10-K
FY FY2025Feb 17, 2026NewAmsterdam Pharma Company N.V. reported a fiscal year 2025 net loss of $203.8 million, driven by significant operating expenses of $248.2 million that far exceeded its $22.5 million in revenue. The company generated substantial interest income of $27.6 million and recorded fair value gains on warrants of $22.8 million, partially offsetting operating losses. Cash flow from operations was negative $147.8...
What Changed Recently
Fundamentals
How The Business Makes Money
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Industry Biotechnology
Company Profile
CIK0001936258
ISINNL00150012L7
Phone31 35 206 2971
AddressGooimeer 2-35, Naarden, 1411 DC, NL
SEC EDGAR